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Randomized controlled trials (RCTs) usually report re-
sults as the overall average of relative effects of health care
interventions, such as hazard ratios or mean differences.
However, treatment effects are unlikely to be homogeneous
across study participants, and averaging effects may
mislead clinicians in the care of individual patients [1,2].
To maximize health gain from limited resources, it is a clin-
ically meaningful question about whether the effect of a
treatment differs by differing characteristics of patients [3].
Subgroup analysis in clinical trials aims to detect subgroup
effects, defined as the difference in treatment effect between
subgroups because of causal interactions [4], to inform clinical
decisions about which patients should or should not receive a
treatment [5,6].However, there arewell-known limitationswith
subgroupanalyses, including inflated falsepositivesdue tomul-
tiple testing and high false negatives due to inadequate statisti-
cal power [7,8]. Although issues related to subgroup analysis
have been debated for decades and numerous guidance on sub-
group analyses has been advocated, controversy remainsess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 Inappropriate specification and reporting of sub-
group analyses remain problematic in recently
published protocols and reports of randomized
controlled trials.
 Subgroup analyses were often reported insuffi-
ciently for assessing the consistency of results of
subgroup analyses across studies, and rationales
for subgroup analyses were very rarely provided
in trial protocols and trial reports.
What this adds to what was known?
 The present study summarized empirical evidence
about what rationales were used for subgroup ana-
lyses in a large number of randomized controlled
trials. Furthermore, this is the first to examine
whether results of subgroup analyses were suffi-
ciently reported to facilitate the checking of consis-
tency in subgroup effects reported.
What is the implication and what should change
now?
 Further research are required to accumulate more
empirical evidence about how and why subgroup
analyses are planned or conducted in clinical trials.
 Methodological and reporting guidance needs to
focus more on sufficient reporting of prespecified
or post hoc subgroup analyses so as to facilitate
checking of consistency in results of subgroup an-
alyses across clinical trials.
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group analyses in clinical trials [9e12]. Recent studies
found that there has been no improvement in the reporting
of subgroup analyses [13,14], and that there were discrep-
ancies between subgroup analyses planned in protocols
and journal publications of clinical trials [15].
Many journals have been accepting and publishing clin-
ical trial protocols so as to promote public access to them
[16,17]. Using a sample of trial protocols published in jour-
nals, this study aimed to assess the appropriateness and ra-
tionales of subgroup analyses planned in trial protocols and
those reported in trial publications.2. Methods
We defined subgroup analyses as those based on partic-
ipant characteristics at baseline. We excluded subgroup an-
alyses defined by intervention characteristics (such asdosages, differences in health care providers), patient
response to treatment, or other events after the start of a
clinical trial.2.1. Identification and inclusion of trial protocols
We included trial protocols published in journals during
2006e2017 and excluded those that met any of the
following exclusion criteria: (1) preclinical trials that
included healthy people, (2) nonrandomized, (3) published
in languages other than English, (4) published before 2006,
(5) nonhuman, and (6) the full text not openly available.
We searched PubMed on March 5, 2018, using key
terms ‘‘study protocol,’’ random*, and ‘‘trial’’ in the title
and located a total of 3,774 records. The located records
were managed by Microsoft Excel (2016) and separated
into five groups by year of publication: protocols pub-
lished during 2006e2009, 2010e2011, 2012e2013,
2014e2015, and 2016e2017. Then we used Excel
RAND command to generate a random number (from
0 to 1) for each of the identified records and ordered them
by the assigned random numbers from the smallest to the
largest. From each of the 5 year groups, we included the
first 100 ranked protocols (starting from the smallest
random number assigned). Because of the small number
of protocols published before 2010, all 83 protocols pub-
lished during 2006e2009 were included. Therefore, we
initially included a total of 483 randomly selected trial
protocols.2.2. Data extraction and synthesis
We finalized a data extraction form (Supplementary
Appendix 1) after pilot testing by two reviewers (J.C.F.
and F.S.) using 10 of the sampled trial protocols. One
reviewer (J.C.F.) then extracted information from the re-
maining sampled protocols, and a second reviewer (F.S.)
thoroughly checked the extracted data.
We used the unique numbers of clinical trial registration
to identify any subsequent publications reporting the results
of trials that corresponded with the included trial protocols
(up to July 31, 2018). We extracted data from the journal
publications by one reviewer (J.C.F.) and checked by a sec-
ond reviewer (F.S.) in line with items used in a previous
study (Supplementary Appendix 1) [15]. The reporting of
subgroup analyses in a trial publication was judged to be
sufficient for cumulative subgroup analyses [18] if the trial
report provided estimated subgroup effects with standard
errors, confidence intervals, or interaction P values [19].
A subgroup effect was considered to be as claimed if the
trial authors explicitly stated in the abstract or discussion/
conclusion that the effect of an intervention was different
between subgroups or that a clear benefit or harm was seen
in one or more subgroups [20].
We calculated the proportion of trial protocols with
planned subgroup analyses, the proportion of trial
19J. Fan et al. / Journal of Clinical Epidemiology 108 (2019) 17e25publications reported subgroup analyses, explored the asso-
ciation of planned or reported subgroup analyses with study
characteristics, and compared subgroup analyses planned in
protocols and reported in trial publications. Data regarding
sample size, journal impact factor, and number of subgroup
analyses were categorized based on percentile distributions.
We used the chi-square test for statistically analyzing cate-
gorical data and nonparametric trend test for ordinal data
(such as ordered groups by year of publication and sample
size).3. Results
3.1. Characteristics of trial protocols and reports
Four of the 483 initially included protocols were eventu-
ally excluded for the following reasons: publication in non-
English language, nonrandomized trial, animal study, and
only the qualitative component of a planned trial. We iden-
tified 280 trial publications corresponding to the included
protocols (see Supplementary Appendix 2 for references
of included trial protocols and publications). The median
number of years between the publication of the protocol
and trial report was three (ranging from 0 to 10 years).
The main characteristics of the 479 included protocols
and the 280 trial publications are shown in Table 1. More
than half of the protocols (53.0%) were published in Trials,
and 83.5% were published in journals with a journal impact
factor ranging from 2.000 to 4.999 in 2017. Most protocols
concerned trials in high-income countries (85.4%) and with
nonindustry funding (85.4%). Of the 479 protocols, 86.2%
were superiority design, 60.5% were multicenter studies,
19.0% were cluster trials, 23.8% had a sample size more
than 500, and 50.1% used objectively measured primary
outcomes (Table 1).
Subgroup analyses were planned in 94 (19.6%) of the
479 protocols (Table 1). The proportion of protocols with
planned subgroup analyses decreased over time
(P 5 0.029), from 25.6% in protocols published during
2006e2009 to 13.3% in those published during
2016e2017 (Table 1). In addition, the specification of sub-
group analyses in protocols was positively associated with
larger sample size (P ! 0.001), multicenter design
(P 5 0.009), and nonindustry funding (P 5 0.036). There
was no statistically significant association between specifi-
cation of subgroup analyses and other trial characteristics in
Table 1 or different clinical fields (Supplementary
Appendix 3).
Fifty-nine (21.1%) of the 280 trial publications reported
subgroup analyses (Table 1). The reporting of subgroup an-
alyses was associated with larger sample size (P! 0.001),
objectively measured primary outcomes (P 5 0.006), and
higher journal impact factor (P 5 0.002). The proportion
of trials reporting subgroup analyses was 12.9% in trials
published in journals with an impact factor !5, compared
with 36.2% in those with an impact factor 10 (Table 1).There was no statistically significant association between
reporting of subgroup analyses in trial publication and other
study characteristics.3.2. Subgroup analyses planned or reported
The main characteristics of the 94 protocols with
planned subgroup analyses and 59 trial publications re-
ported subgroup analyses are shown in Table 2. All the
planned subgroup analyses were exploratory, including
nine (9.6%) that mentioned subgroup effects in trial objec-
tives. Of the 94 protocols, only four provided justification
for the planned subgroup analyses, three considered issues
concerning statistical power; and none explicitly antici-
pated the direction of subgroup effects (Table 2). Test for
interaction was mentioned in only 31.9% of the 94 trial pro-
tocols with planned subgroup analyses. Subgroup variables
were explicitly listed in 78 (83.0%) of the 94 trial protocols,
including disease characteristics (78.2%), age (30.8%),
gender (29.5%), socioeconomic factors (26.9%), ethnicity
(9.0%), and study center (9.0%). Cut-points were explicitly
defined in only 27.3% of the 77 protocols with subgroups
by continuous variables.
Of the 59 trial publications that reported subgroup ana-
lyses, more than half (55.9%) had not specified any sub-
group analyses in the corresponding protocols (Table 2).
Nine trial reports stated that the subgroup analyses were
prespecified although there was no mention of any sub-
group analyses in the corresponding protocols. Seven trial
reports tried to justify at least one of the subgroup analyses,
only one anticipated the direction of possible subgroup ef-
fects, and none considered issues regarding statistical po-
wer of subgroup analysis. Statistical test for interaction or
subgroup effects was not conducted in 23 (39.0%),
including 8 of the 20 trial publications with subgroup effect
claims. Results of subgroup analyses were insufficiently re-
ported in 21 (35.6%) of the 59 trial publications.
When trial protocols and publications were categorized
into two groups by year of publication (2006e2013 and
2014e2018), there were no improvements over time in
the use of a statistical test for interaction in prespecification
of subgroup analyses in protocols or in reporting of suffi-
cient data on results of subgroup analyses (Table 3).3.3. Justification for subgroup analyses
Only 4 of the 94 trial protocols with planned subgroup
analyses provided some justifications or rationales for sub-
group analyses (Supplementary Appendix 4). In two proto-
cols [21,22], subgroup analyses were based on findings
from previous clinical studies. The planned subgroup ana-
lyses were simply based on the suspected differences in
treatment effect by subgroups, without giving more details,
in the remaining two trial protocols [23,24]. Results of
these four RCTs have been published, and all reported no
subgroup effects.
Table 1. The main characteristics of included protocols of randomized controlled trials
Characteristics
RCT protocols Trial publications
N Planned SGAs (%) N Reported SGAs (%)
Total 479 94 (19.6) 280 59 (21.1)
Year of publication
2006e2009 82 21 (25.6) 11 5 (45.5)
2010e2011 100 23 (23.0) 29 5 (17.2)
2012e2013 99 18 (18.2) 49 8 (16.3)
2014e2015 100 19 (19.0) 80 21 (26.3)
2016e2017/18 98 13 (13.3) 111 20 (18.0)
Journal impact factor
!2.000 32 4 (12.5) 27 2 (7.4)
2.000e4.999 400 83 (20.8) 112 16 (14.3)
5.000e9.999 27 4 (14.8) 82 19 (23.2)
10.000 0 e 58 21 (36.2)
Geographical region
Europe 252 53 (21.0) 150 38 (25.3)
Asia 61 13 (21.3) 25 5 (20.0)
Oceania 61 10 (16.4) 46 7 (15.2)
North America 59 10 (17.0) 36 4 (11.1)
South America 18 2 (11.1) 7 1 (14.3)
Africa 13 1 (7.7) 0 0 (0.0)
Multiple 15 5 (33.3) 8 4 (50.0)
Country income category
Developed 409 83 (20.3) 250 54 (21.6)
Less developed 63 8 (12.7) 26 3 (11.5)
Mixed 7 3 (42.9) 4 2 (50.0)
Funding source
Nonindustry 409 87 (21.3) 245 51 (20.8)
Industry 28 5 (17.9) 14 1 (7.1)
Mixed/other 42 2 (4.8) 13 7 (53.8)
Trial design type
Superiority 384 81 (21.1) 239 50 (21.1)
Exploratory 87 12 (13.8) 38 9 (23.7)
Noninferiority 8 1 (12.5) 3 0 (0.0)
No. of centers
Multicenter 290 68 (23.5) 177 43 (24.3)
Single center 189 26 (13.8) 103 16 (15.5)
Cluster trials
Yes 91 21 (23.1) 61 12 (19.7)
No 388 73 (18.8) 219 47 (21.5)
Sample size category
100 121 10 (8.3) 72 5 (6.9)
101e250 126 23 (18.3) 74 13 (17.6)
251e500 113 26 (23.0) 63 22 (34.9)
O500 114 35 (30.7) 71 19 (26.8)
Type of primary outcome
Objective 240 51 (21.3) 134 39 (29.1)
Subjective 234 41 (17.5) 145 20 (13.8)
Mixed/unclear 5 2 (40.0) 1 0 (0.0)
Abbreviations: RCT, randomized controlled trials; SGA, subgroup analysis.
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Table 2. Characteristics of subgroup analyses planned in trial protocols or reported in trial publications
Variables Planned SGAs in trial protocols Reported SGAs in trial publications
Total 94 (100%) 59 (100%)
Prespecification
Prespecified 94 (100%) 26 (44.1%)
Post hoc 0 33 (55.9%)
Justification for SGAs
Provided 4 (4.3%) 7 (11.9%)
Not provided 90 (95.7%) 52 (88.1%)
Described SGA variables
Yes 78 (83.0%) e
No 16 (17.0%) e
Anticipated SGE direction
Yes 0 (0%) 1 (1.7%)
No 94 (100%) 58 (98.3%)
Considered power for SGAs
Yes 3 (3.2%) 0 (0%)
No 91 (96.8%) 59 (100%)
Test for interaction
Yes 30 (31.9%) 36 (61.0%)
No 64 (68.1%) 23 (39.0%)
No. of SGAs
1e3 45 (47.9%) 22 (40.0%)
4þ or unclear 49 (52.1%) 33 (60.0%)
Cut-points defined for continuous SGV
Yes 21 (27.3%)
No 56 (72.7%) e
NA 17 (NA) e
Sufficient SGA results
Yes e 38 (64.4%)
No e 21 (35.6%)
Subgroup effects claims
Yes e 20 (33.9%)
No e 39 (66.1%)
Abbreviations: SGA, subgroup analysis; SGE, subgroup effects; SGV, subgroup variables.
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provided in 7 of the 59 trial publications with subgroup an-
alyses (Supplementary Appendix 4) although no justifica-
tions were mentioned in any of the corresponding
protocols. All justified subgroup analyses according to find-
ings from previous studies. In one case, post hoc subgroup
analyses were conducted as a response to critics of previous
clinical trials with negative results [25]. There were no sta-
tistically significant subgroup effects reported in the seven
trial publications.
Of the 221 trial publications that did not report subgroup
analyses, nine mentioned reasons for not conducting or re-
porting any subgroup analyses. Inadequate statistical power
and inadequate recruitment of participants belonging to
certain subgroups were the reasons for lack of subgroup an-
alyses in trial reports, except for one which stated that sub-
group analyses would be reported in separate publications.4. Discussion
We found that subgroup analyses were planned in 19.6%
of the 479 RCT protocols published in journals and re-
ported in 21.1% of the 280 corresponding trial publications.
The proportion of trial protocols with planned subgroup an-
alyses was associated with sample size, multicenter design,
and nonindustry funding. There was a reduced proportion
of protocols with planned subgroup analyses over time. Jus-
tifications for subgroup analyses were rarely provided
(4.3%), mainly based on findings from previous studies or
suspected possibility of subgroup effects.
The reporting of subgroup analyses in trial publications
was positively associated with sample size, objectively
measured outcomes, and journal impact factors. More than
half of the subgroup analyses reported in trial publications
were post hoc, without specification in the corresponding
Table 3. Interaction test for subgroup effects and adequate result reporting by grouped publication year
Characteristics
Trial protocols Trial reports
N Yes (%) N Yes (%)
Statistical test for subgroup effect or interaction
2006e2013 62 21 (33.9) 18 13 (72.2)
2014e2018 32 9 (28.1) 41 23 (56.1)
Sufficient data on subgroup analyses reporteda
2006e2013 e e 18 12 (66.7)
2014e2018 e e 41 26 (63.4)
Specification of subgroup analyses in protocols
2006e2013 e e 18 9 (50.0)
2014e2018 e e 41 17 (41.5)
a The reporting of subgroup analyses in a trial publication was judged to be sufficient for cumulative subgroup analyses if the trial report pro-
vided estimated subgroup effects with standard errors, confidence intervals, or interaction P values [19].
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as prespecified in some trial publications although none
were mentioned in the corresponding protocols. ComparedTable 4. Comparison with previous studies of subgroup analyses in randomi
Characteristics The present study Kasenda et al. 2
Source of trial protocols 479 trial protocols
published in journals
during 2006e2017.
894 protocols ap
six research et
committees in
Switzerland, G
and Canada du
e2003.
Trial protocols
Protocols with planned
SGAs
19.6% (94/479) 28.2% (252
Justification/rationale for
planned SGAs
4.3% (4/94) e
Anticipated direction of
SGE for planned SGAs
0.0% (0/94) 4.0% (10/
Appropriate test for
interaction or subgroup
effects
31.9% (30/94) 34.5% (87/
Full trial publications
Reporting of SGAs 21.1% (59/280) 47.8% (246
Post hoc SGAs without
specification in
protocol
55.8% (33/59) 19.5% (48/
Prespecification stated in
trial reports, but not in
protocols
25.7% (9/35) 34.6% (28/
Provided rationales for
SGAs
11.9% (7/59) e
Anticipated the direction
of SGE
1.7% (1/57) 4.5% (11/
Considered statistical
power for SGAs
0.0% (0/57) 2.4% (6/2
Appropriate test for
interaction
61.0% (36/59) 39.0% (96/
Sufficient reporting of
SGAs
64.4% (38/59) e
Claimed any SGEs 33.9% (20/59) 35.0% (86/
Abbreviations: SGAs, subgroup analyses; SGEs, subgroup effects.with trial protocols, relatively more trial reports tried to
retrospectively justify subgroup analyses. Seven of the 59
trial reports with subgroup analyses provided somezed trials
014 [15] Chan et al. 2008 [26] Al-Marzouki et al. 2008 [27]
proved by
hics
ermany,
ring 2000
70 protocols approved by
the scientific ethics
committees for
Copenhagen and
Frederiksberg, Denmark
in 1994e1995.
37 trial protocols with
summaries published on
the Lancet’s Web site as
of June 2007.
/894) 18.6% (13/70) 48.6% (18/37)
e 2.7% (1/37)
252) e e
252) e e
/515) 28.6% (20/70) 75.7% (28/37)
246) 60.0% (12/60) 39.3% (11/28)
81) 57.1% (4/7) e
e e
246) e e
46) e e
246) e e
e e
246) e e
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able in the corresponding trial protocols.
Testing for subgroup effects or interaction was planned
in 31.9% of the 94 protocols and conducted in 61.0% of
the 59 trial publications. There was no improvement over
time in appropriate testing for interaction in either trial pro-
tocols or reports or in reporting of results of subgroup an-
alyses in trial publications.4.1. Comparison with previous studies
Several previous studies have evaluated subgroup ana-
lyses in study protocols and their corresponding study re-
ports [15,26e28]. Results of the present and previous
relevant studies of RCT protocols [15,26,27] are shown in
Table 4. The proportion of trial protocols with planned sub-
group analyses in the present study was 19.6%, which was
similar to one previous study [26], but lower than was re-
ported in other studies (from 28.2% [15] to 48.6% [27]).
Differing sources of trial protocols and year periods may
explain some differences in planned subgroup analyses
across studies. Similar to a previous study [15], we found
that specification of subgroup analyses in trial protocols
was positively associated with sample size and multicenter
design. However, contrary to a previous study [15], we
observed a significant association between subgroup anal-
ysis specification and nonindustry funding. As in previous
studies, we found that trial protocols rarely anticipated
the direction of subgroup effects, and there were discrep-
ancies between subgroup analyses planned in trial protocols
and presented in trial reports. Available evidence indicated
that inadequate prespecification of subgroup analyses in
trial protocols and reporting of subgroup analyses in trial
publications have not improved over decades. A previous
study (not included in Table 4 because of a mix of different
study designs) found that justifications for subgroup ana-
lyses were provided in 16.3% of 76 grant applications
[28]. Justifications for subgroup analyses were rarely pro-
vided in RCT protocols; which was 4.3% in the present
study and only 2.7% in a small study of 37 trial protocols
[27].4.2. Strengths and limitations
This is the first study using a random sample of trial pro-
tocols published in journals and corresponding trial reports
to examine planned and reported subgroup analyses in
RCTs. Findings from the present study update and further
strengthen existing empirical evidence regarding the appro-
priateness of subgroup analyses in clinical research. Partic-
ularly, the present study summarized empirical evidence
about how specified subgroup analyses were justified or
what rationales were used for subgroup analyses in a large
number of RCTs. Furthermore, the present study is the first
to examine whether results of subgroup analyses were suf-
ficiently reported to facilitate the checking of consistency insubgroup effects reported and the conduct of cumulative
subgroup analyses [18]. Similar to cumulative meta-
analysis [29], cumulative subgroup analysis refers to a se-
ries of repeated meta-analyses of subgroup effects after
adding data from each new trial chronologically.
The present study included protocols of trials conducted
in more regions or countries compared with previous
studies that considered trials restricted in high-income
countries in Europe or North America. However, protocols
published in journals may be systematically different from
those approved by research ethics committees. For
example, the proportion of trials with industry funding
was 17.9% in the present study compared with 60.2% in
a previous study of trial protocols approved by research
ethics committees in Europe or Canada [15]. Because of
the restriction of available resources and time, we included
only a random sample of 479 from a total of 3,774 pub-
lished protocols identified from PubMed. Furthermore, we
did not check any amendments of trial protocols or statisti-
cal analysis plans of trials for possible changes in specifica-
tion of subgroup analyses. However, we believe that the
main findings from the present study were unlikely to be
materially different by including more published protocols
or by obtaining additional information from protocol
amendments and statistical analysis plans. These assump-
tions might be worthy of further evaluation of the literature
in the future.
4.3. Implications
4.3.1. For journal editors and peer reviewers
Specification of subgroup analyses in trial protocols
published in journals could be much improved if journal
editors and peer reviewers identified inappropriate sub-
group analyses before protocols are accepted for publica-
tion. For example, investigators could be encouraged to
provide justifications or rationales for planned subgroup an-
alyses, to anticipate the direction of subgroup effects, and
to use appropriate statistical test for interaction. Journal ed-
itors and peer reviewers may need to improve their own un-
derstanding of what are important issues for
prespecification of subgroup analyses in trial protocols.
Attention from journal editors and peer reviewers is also
needed to the appropriate reporting of subgroup analyses
in trial publications. For example, the discrepancies in sub-
group analyses between protocols and trial reports could be
avoided or explained by checking the corresponding trial
protocols before accepting trial reports for publication.
The journal editors and peer reviewers should also ensure
sufficient reporting of results of subgroup analyses for cu-
mulative meta-analyses of subgroup effects.
4.3.2. For researchers
Medical and health researchers need to understand how
to plan and conduct appropriate subgroup analyses in clin-
ical studies. During the preparation of trial protocols,
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considered. Justifications and rationales for planned sub-
group analyses should be provided although subgroup an-
alyses should also be allowed purely for exploratory
purpose. In trial publications, both prespecified and post
hoc subgroup analyses should be reported with sufficient
data for cumulative subgroup analyses [19]. The present
study found that some trial publications did not report sub-
group analyses because of the small sample size. For a sin-
gle study, the sample size may be too small to reveal
significant subgroup effects. However, if multiple small
studies on the same topic conduct the same subgroup an-
alyses, cumulative subgroup analyses may show how
consistent are results of subgroup analyses across individ-
ual trials and provide a more valid overall estimate of sub-
group effects [18].
4.3.3. Methodological and reporting guidance
There is much existing guidance aiming to reducing
inappropriate use of subgroup analyses in clinical research
[5,6,8,30e32]. The key points for assessing the credibility
of subgroup analyses in clinical trials include prespecifica-
tion of subgroup analyses in protocols, a small number of
subgroup analyses conducted, appropriate statistical test
for subgroup effects, and consistency in results of subgroup
analyses across trials. As attention has been focused mainly
on the problem of inflated false positives, efforts to avoid
inappropriate subgroup analyses may have resulted in a
recent reduction in the proportion of trial protocols with
planned subgroup analyses as shown in the present study.
If fewer or no subgroup analyses are conducted in clinical
trials, it will be difficult or impossible to examine the con-
sistency in results of a subgroup analysis across different
trials, and valuable data from clinical research will be
wasted [18]. Therefore, methodological guidance on sub-
group analyses in clinical research should emphasize the
importance of sufficient reporting of results of all prespeci-
fied or post hoc subgroup analyses conducted, rather than
insist on only a small number of planned subgroup ana-
lyses. With sufficient reporting of subgroup analyses from
multiple trials, some problems related to inappropriate sub-
group analyses, such as lack of test for interaction and false
positive or false negative subgroup effects in isolated indi-
vidual trials, could be properly corrected with evidence
accumulation.
4.3.4. Further research required
The present study found very limited empirical evi-
dence regarding justifications or rationales for subgroup
analyses planned or conducted in clinical trials.
Although all existing guidance on clinical research have
emphasized the importance of a priori specification of
subgroup hypotheses in clinical trials, there are no guid-
ance specifically about how to specify a priori subgroup
hypotheses at the design stage of a clinical trial. Further
research are required to accumulate more empiricalevidence about how and why subgroup analyses are
planned or conducted in clinical trials and what measures
could be taken to improve the efficient use of data from
clinical trials to appropriately identify clinically mean-
ingful subgroup effects.5. Conclusions
Inappropriate specification and reporting of subgroup
analyses remain problematic in published protocols and re-
ports of RCTs although the trial protocols published more
recently are less likely to plan subgroup analyses than those
published earlier. Justifications or rationales for subgroup
analyses were only rarely provided in trial protocols and
trial reports. Methodological and reporting guidance needs
to focus more on sufficient reporting of prespecified or post
hoc subgroup analyses so as to facilitate checking of con-
sistency in results of subgroup analyses across clinical
trials.
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Supplementary data to this article can be found online at
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